Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clofibrate in type II hyperlipoproteinemia.

J Ditzel, H O Bang

    Acta Medica Scandinavica
    |January 1, 1976
    PubMed
    Summary

    Clofibrate effectively lowers lipids in patients with type II hyperlipoproteinemia (HLP), significantly reducing cholesterol and triglycerides over 60 weeks. The study found no significant clinical side effects, indicating good safety for this lipid-lowering treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Long-Range Transverse-Momentum Correlations and Radial Flow in Pb-Pb Collisions at the LHC.

    Physical review letters·2026
    Same author

    Search for Quasiparticle Scattering in the Quark-Gluon Plasma with Jet Splittings in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

    Physical review letters·2025
    Same author

    First Measurement of A=4 Hypernuclei and Antihypernuclei at the LHC.

    Physical review letters·2025
    Same author

    Probing Strangeness Hadronization with Event-by-Event Production of Multistrange Hadrons.

    Physical review letters·2025
    Same author

    Measurements of Chemical Potentials in Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

    Physical review letters·2024
    Same author

    Observation of Medium-Induced Yield Enhancement and Acoplanarity Broadening of Low-p_{T} Jets from Measurements in pp and Central Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

    Physical review letters·2024

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Type II hyperlipoproteinemia (HLP) is characterized by elevated serum lipids.
    • Effective lipid-lowering agents are crucial for managing HLP and reducing cardiovascular risk.

    Purpose of the Study:

    • To evaluate the safety and lipid-lowering efficacy of clofibrate in patients with type II HLP.
    • To assess the effect of clofibrate on uric acid levels.

    Main Methods:

    • A double-blind, randomized study involving 28 patients with type II HLP.
    • Treatment with clofibrate over a 60-week observation period.
    • Monitoring of serum lipid profiles (cholesterol, triglycerides) and uric acid levels.

    Main Results:

    • Significant reductions in serum cholesterol for type IIa HLP and triglycerides/cholesterol for type IIb HLP (p < 0.01).
    • 65% of patients achieved at least a 25% reduction in serum cholesterol.
    • A significant reduction in uric acid was observed during the initial treatment phase (p < 0.05).
    • Minor, persistent reductions in Hb, hematocrit, and alkaline phosphatase were noted without clinical significance.

    Conclusions:

    • Clofibrate demonstrates significant efficacy in reducing lipids in patients with type II hyperlipoproteinemia.
    • The drug is considered safe for many patients with type II HLP, with no significant clinical side effects reported.

    Related Experiment Videos